『Thoughts on the Market』のカバーアート

Thoughts on the Market

Thoughts on the Market

著者： Morgan Stanley
無料で聴く

このコンテンツについて

Short, thoughtful and regular takes on recent events in the markets from a variety of perspectives and voices within Morgan Stanley.

© Morgan Stanley & Co. LLC 個人ファイナンス 経済学
エピソード
  • Standing by Our Outlook

    Standing by Our Outlook
    2025/06/06
    Morgan Stanley’s midyear outlook defied the conventional view in a number of ways. Our analysts Serena Tang and Vishy Tirupattur push back on the pushback to their conclusions, explaining the thought process behind their research. Read more insights from Morgan Stanley.----- Transcript -----Serena Tang: Welcome to Thoughts on the Market. I'm Serena Tang, Morgan Stanley's Chief Cross-Asset StrategistVishy Tirupattur: And I'm Vishy Tirupattur, Morgan Stanley's Chief Fixed Income Strategist.Serena Tang: Today's topic, pushback to our outlook.It's Friday, June 6th at 10am in New York.Morgan Stanley Research published our mid-year outlook about two weeks ago, a collaborative effort across the department, bringing together our economist views with our strategist high conviction ideas. Right now, we're recommending investors to be overweight in U.S. equities, overweight in core fixed income like U.S. treasuries, like U.S. IG corporate credit. But some of our views are out of consensus.So, I want to talk to you, Vishy, about pushback that you've been getting and how we pushback on the pushback.Vishy Tirupattur: Right. So, the biggest pushback I've gotten is a bit of a dissonance between our economics narrative and our markets narrative. Our economics narrative, as you know, calls for a significant weakening of economic growth. From about – for the U.S. – 2.5 percent growth in 2024 goes into 1 percent in 2025 and in 2026. And Fed doesn't cut rates in 2025, and cuts seven times in 2026.And if you look at a somewhat uninspiring outlook for the U.S. economy from our economists – reconciling an uninspiring economic outlook on the U.S. economy with the constructive view we have on U.S. assets, equities, credit, treasuries – that's been a source of contention. So, reconciling an uninspiring outlook on the U.S. economy with a constructive view on risk assets, as well as risk-free assets in the U.S. economy – so, equities, credit, as well as government bonds – has been a somewhat contentious issue.So how do we reconcile this? So, my pushback to the pushback is the following; that they are different plot lines across different asset classes. So, our economists have slowing of the economy – but not an outright recession. Our economists don't have rate cuts in 2025 but have seven rate cuts in 2026.So, if you look at the total number of rate cuts that are being priced in by the markets today, roughly about two rate cuts in [20]25, and about between two and three rate cuts in 2026, we expect greater policy easing than what's currently priced in the markets. So that makes sense for our constructive view on interest rates, and in government bonds and in duration that makes sense.From a credit point of view, we enter this point with a much better credit fundamentals in leverage and coverage terms. We have the emergence of a total yield-based buyer base, which we think will be largely intact at our expectations, and you layer on top of that – the idea that growth slows but doesn't fall into recession is also constructive for higher quality credit. So that explains our credit view.From an equities view, the drawdowns that we experienced in April, our equity strategists think marks the worst outcomes from a policy point of view that we could have had. That has already happened. So looking forward, they look for EPS growth over the course of the next 12 months. They look for benefits of deregulation to kick in. So, along with that seven rate cuts, get them to be comfortable in being constructive about their views on equities. So all of that ties together.Serena Tang: And I think what you mentioned around macro not being the markets is important here. Because when we did some analysis on historical periods where you had low growth and low inflation, actually in that kind of a scenario equities did fine. And corporate credit did fine. But also, in an environment where you have rather unencouraging growth, that tends to map onto a slightly risk-off scenario. And historically that's also a kind of backdrop where you see the dollar strengthen.This time out, we have a very out of consensus view; not that the dollar will weaken, that seems quite consensus. But the degree of magnitude of dollar weakening. Where have you been getting the most pushback on our expectations for the dollar to depreciate by around 9 percent from here?Vishy Tirupattur: So, the dollar weakness in itself is not out of consensus, largely driven by narrowing of free differentials; growth differentials. I think some of the difference between the extent of weakness that we are projecting comes from the assessment on the policy and certainty. So, the policy uncertainty adds a greater degree of risk premia for taking on U.S. assets.So, in our forecast, we take into account not only the differentials in rates and growth, but also in the policy uncertainty and the risk premia that the investors would demand in the face of that kind of policy ...
    続きを読む 一部表示
    10 分
  • 5 Reasons the Obesity Drug Market Remains Strong

    5 Reasons the Obesity Drug Market Remains Strong
    2025/06/05

    The global market for obesity drugs is expanding. Our U.S. Pharma and Biotech Analyst Terrence Flynn discusses what’s driving the next stage of global growth for GLP-1 medicines.


    Read more insights from Morgan Stanley.


    ----- Transcript -----


    Terrence Flynn: Welcome to Thoughts on the Market. I'm Terrence Flynn, Morgan Stanley's U.S. Pharma and Biotech Analyst. The market for obesity medicines is at an inflection point, and today I'll focus on what's driving the next stage of global growth.

    It's Thursday, June 5th at 2pm in New York.

    GLP-1 medicines have been viewed by many stakeholders as one of the most transformative medications in the market today. They've exploded in popularity over the last few years and become game changers for many people who take them. These drugs have large cap biopharma companies racing to innovate. They've had ripple effects on food, fitness, and fashion. They truly are a major market force. And now we're on the cusp of a significant broadening of use of these medicines.

    Currently the U.S. is the largest consumer in the world of GLP-1s. But new versions of these medicines suggest that this market will extend beyond the U.S. to significantly larger numbers of patients globally. On our estimate, the Total Addressable Market or TAM for obesity medications should reach $150 billion globally by 2035, with approximately [$]80 billion from the U.S. and [$]70 billion from international markets.

    Now this marks a meaningful increase from our 2024 forecast of [$]105 billion and reflects a greater appreciation of opportunities outside of the U.S. We think obesity drug adoption will likely accelerate as patients and providers become more familiar with the new products and as manufacturers address hurdles in production, distribution, and access.

    Current adoption rates of GLP-1 treatments within the eligible obesity population are about 2 to 3 percent. This is in the U.S., and roughly 1 percent in the rest of the world. Now, when we look out further, we anticipate these figures to surge to 20 percent and 10 percent respectively, really driven by five things.

    First, after a period of shortages, supply constraints have improved, and the drug makers are investing aggressively to increase production. Second new data show that obesity drugs have broader clinical applications. They can be used to treat coronary heart disease, stroke, hypertension, kidney disease, or even sleep apnea. They could also potentially fight Alzheimer's disease, neuropsychiatric conditions, and even cancer.

    Third, we think coverage will expand as obesity drugs are approved to treat diseases beyond obesity. Public healthcare coverage through Medicare should also broaden based on these expected approvals. Fourth, some drug makers are successfully developing obesity drugs, in pill form instead of injectables. Pills are of course easier to administer and can reach global scale quickly. And finally, drug makers are also developing next gen medications with even higher efficacy, new mechanisms of action, and more convenient, less frequent dosing.

    All in all, we think that over the next decade, broader GLP-1 adoption will extend well beyond biopharma. We expect significant impacts on medical technology, healthcare services, and consumer sectors like food, beverages, and fashion, where changes in patient diets could reshape market dynamics.

    Thanks so much for listening. If you enjoy the show, please leave us a review wherever you listen. And share Thoughts on the Market with a friend or colleague today.
    続きを読む 一部表示
    4 分
  • Midyear U.S. Credit Outlook: Why Investors Should Be Selective

    Midyear U.S. Credit Outlook: Why Investors Should Be Selective
    2025/06/04
    Our analysts Andrew Sheets and Vishwas Patkar take stock of the U.S. credit market, noting which segments are on firm footing going into a period of slower growth.Read more insights from Morgan Stanley.----- Transcript -----Andrew Sheets: Welcome to Thoughts On the Market. I'm Andrew Sheets, Head of Corporate Credit Research at Morgan Stanley.Vishwas Patkar: And I'm Vishwas Patkar, Head of U.S. Credit Strategy at Morgan Stanley.Andrew Sheets: Today on the program, we're going to have the first in a series of conversations covering our outlook for credit around the world.It's Wednesday, June 4th at 2pm in London.Vishwas Patkar: And 9am in New York.Andrew Sheets: Vishwas, along with many of our colleagues at Morgan Stanley, we recently updated our 12-month outlook for credit markets around the world. Focusing on your specialty, the U.S., how do you read the economic backdrop and what do you think it means for credit at a high level?Vishwas Patkar: So, our central scenario of slowing growth, somewhat firm inflation and no rate cuts from the Fed until the first quarter of 2026 – when I put all of that together, I view that as somewhat mixed for credit. It's good for certain segments of the market, not as good for others.I think the positive on the one side is that with the recent de-escalation in trade tensions, recession risks have gone lower. And that's reflected in our economists' view as well. I think for an asset class like credit, avoiding that drill downside tail I think is important. The other positive in the market today is that the level of all in yields you can get across the credit spectrum is very compelling on many different measures.The negative is that we are still looking at a fair bit of slowing in economic activity, and that's a big downshift from what we've been used to in the past few years. So, I would say we're certainly not in the Goldilocks environment that we saw for credit through the second half of last year. And it's important here for investors to be selective around what they invest in within the credit market.Andrew Sheets: So, Vishwas, you kind of alluded to this, but you know, 2025 has been a year that so far has been dominated by a lot of these large kind of macro questions around, you know, what's going to happen with tariffs. Big moves in interest rates, big moves in the U.S. dollar. But credit is an asset class that's, you know, ultimately about lending to companies. And so how do you see the credit worthiness of U.S. corporates? And how much of a risk is there that with interest rates staying higher for longer than we expected at the start of the year – that becomes a bigger problem?Vishwas Patkar: Yeah, sure. I think it's a very important question Andrew because I think taking a call on markets based on the gyrations in headlines is very hard. But in some ways, I think this question of the credit worthiness of U.S. companies is more important and I think it really helps us filter the signal from the noise that we've seen in markets so far this year.I would say broadly, the health of corporate balance sheets is pretty good and, in some ways, I think it's maybe a more distinguishing feature of this cycle where corporate credit overall is on a firmer footing going into a period of slower growth – than what we may have seen in prior instances. And you can sort of look at this balance sheet health along a few different lines.In aggregate, we haven't really seen credit markets grow a lot in the last few years. M&A activity, which is usually a harbinger of corporate aggression, has also been fairly muted in absolute terms. Corporate balance sheet leverage has not grown. And I think we've been in this high-interest rate environment, which has kept some of these animal spirits at bay. Now what this means is, that the level of sensitivity of credit markets to a slow down in the economy is somewhat lower.It does not mean that credit markets can remain immune no matter what happens to the economy. I think it's clear if we get a recession, spread should be a fair bit wider. But I think in our central scenario, it makes us more confident than otherwise that credit overall can hold up okay.Now your question around the risk of rates staying higher. This I think goes back to my point about where in the credit market you're looking. I think up the quality spectrum, I think there are actually – there's a lot of demand tailwinds for credit given the pickup in sponsorship we've seen from insurance companies and pension funds in this cycle.At the other end of the quality spectrum, if you're looking at highly levered capital structures, that's where I think the risk of interest rates being high can lead to defaults being sort of around average levels and higher than they would otherwise be.Andrew Sheets: So, Vishwas, kind of sticking with that central scenario, kind of briefly, what would be a segment of U.S. credit that you think offers some of the best risk adjusted ...
    続きを読む 一部表示
    7 分

Thoughts on the Marketに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。